Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Passage Bio, Inc. is a biotechnology company focused on the development of gene therapies for serious central nervous system (CNS) disorders, particularly rare, inherited neurodegenerative diseases. The company operates within the biotechnology and gene therapy industries, leveraging adeno-associated virus (AAV) vector technology to deliver therapeutic genes directly to the CNS. Its historical strategy centered on developing one-time, potentially disease-modifying treatments for conditions with significant unmet medical need.
The company was founded in 2017 as a spinout from research conducted at the Children’s Hospital of Philadelphia (CHOP), with a scientific foundation in translational neuroscience and gene therapy. Passage Bio advanced several early-stage CNS gene therapy programs into clinical development. However, beginning in 2022 and continuing through 2023, the company significantly changed direction following pipeline reprioritizations, workforce reductions, and the divestiture of substantially all operating assets, fundamentally altering its business model.
Business Operations
Historically, Passage Bio’s operations were organized around the research and development of AAV-based gene therapies targeting monogenic CNS disorders, including frontotemporal dementia, Krabbe disease, metachromatic leukodystrophy, and GM1 gangliosidosis. These activities encompassed preclinical research, clinical trial execution, regulatory engagement, and manufacturing coordination through third-party partners. The company did not commercialize products and generated no product revenue.
As of late 2023, Passage Bio ceased active clinical development and no longer conducts internal research operations. The company sold substantially all of its gene therapy assets and related intellectual property to GEMMA Biotherapeutics, Inc., a newly formed, privately held gene therapy company. Following this transaction, Passage Bio’s remaining operations consist primarily of managing residual corporate obligations and evaluating strategic alternatives. Data inconclusive based on available public sources regarding any new operating business established after the asset sale.
Strategic Position & Investments
Prior to its asset divestiture, Passage Bio’s strategic position was based on its exclusive licenses to foundational CNS gene therapy technologies developed at CHOP and its focus on intrathecal and intracerebral AAV delivery. The company pursued a strategy of advancing multiple rare-disease programs in parallel to clinical proof of concept. This strategy was materially revised due to capital constraints, clinical complexity, and shifting market conditions for early-stage gene therapy companies.
The most significant strategic transaction was the sale of its core pipeline, preclinical assets, and related licenses to GEMMA Biotherapeutics, Inc. in 2023. Following this transaction, Passage Bio stated that it would focus on maximizing shareholder value through potential mergers, acquisitions, asset sales, or other strategic transactions. No verified public disclosures confirm new investments, acquisitions, or operating subsidiaries beyond this point.
Geographic Footprint
Passage Bio is headquartered in the United States, with its principal executive offices historically located in Philadelphia, Pennsylvania. During its active development phase, the company’s operations and clinical trial activities were primarily U.S.-based, with limited international engagement through research collaborations and clinical sites outside the U.S. as required for rare-disease studies.
The company did not maintain significant international subsidiaries or commercial operations abroad. Following the divestiture of its operating assets, its geographic footprint has been substantially reduced and is largely administrative in nature. Data inconclusive based on available public sources regarding any ongoing international operational presence.
Leadership & Governance
Passage Bio was founded by a group of academic and industry leaders with expertise in gene therapy and neuroscience. Governance and leadership evolved over time in response to strategic and operational changes, particularly during the company’s restructuring and asset sale period. The board of directors has played a central role in overseeing strategic alternatives following the cessation of R&D activities.
Key executives during and following the strategic transition include:
- William J. Lundstrom, Ph.D., J.D. – Chief Executive Officer
- William (Bill) Chou, M.D. – President and Chief Operating Officer (during active development period)
- Erin McKenna – Chief Financial Officer
- David R. Main, Ph.D. – Senior Vice President, Technical Operations (prior to asset divestiture)
Leadership publicly articulated a fiduciary focus on capital preservation and shareholder value maximization after the sale of substantially all operating assets, rather than continued independent product development.